Xbrane Biopharma
0,255 SEK +7,38%2 investorer følger denne virksomhed
Xbrane Biopharma is a biotechnology company. The company specializes in research and development of drugs for the treatment of critical illnesses. Today, the business is focused on research in microspherical technology and in the development of protein molecules. The products are used in the treatment of prostate cancer and endometriosis, as well as in rare and serious eye diseases. The company's head office is located in Solna.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
XBRANE
Daglig lav / høj pris
0,238 / 0,255
SEK
Markedsværdi
389,25 mio. SEK
Aktieomsætning
1,93 mio. SEK
Volumen
7,8 mio.
Seneste videoer
Finanskalender
Delårsrapport
28.08.2024
Delårsrapport
24.10.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Ashkan Pouya | 11,9 % | 11,9 % |
Håkan Stödberg | 4,7 % | 4,7 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Xbrane Provides update on timing of re-submission of BLA for ranibizumab biosimilar candidate
Xbrane successfully scales up Xdivane™- biosimilar candidate to Opdivo® - and run an active partnering process
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Redeye: Xbrane Biopharma Q1 2024 - Approaching an eventful second half of the year
![Xbrane Biopharma, Webcast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/411e9613-0432-4929-b319-2f872846e546.png)
Xbrane Biopharma, Webcast with teleconference, Q1, 2024
Xbrane Biopharma releases Interim Report for January-March 2024
![Xbrane Biopharma, Pressconference, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/00babe22-3db0-40bb-b063-e03d502f97a0.png)
Xbrane Biopharma, Pressconference, 2024
Invitation to presentation of Xbrane Biopharma’s interim report January – March 2024 on May 16, 2024
Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US
Announcement from Xbrane Biopharma's annual general meeting
![Xbrane Biopharma, Pressconference, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/54f5ed3b-c9b5-464b-8581-b4e3226fdf22.png)